Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M. Jacobson CA, et al. Among authors: spooner c. Transplant Cell Ther. 2024 Jan;30(1):77.e1-77.e15. doi: 10.1016/j.jtct.2023.10.017. Epub 2023 Oct 27. Transplant Cell Ther. 2024. PMID: 37890589 Free article.
Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
Kersten MJ, Qiao Y, Shah R, Solem C, Snider JT, To C, Cheng P, Spooner C, Perales MA. Kersten MJ, et al. Among authors: spooner c. Transplant Cell Ther. 2023 May;29(5):335.e1-335.e8. doi: 10.1016/j.jtct.2023.01.008. Epub 2023 Jan 14. Transplant Cell Ther. 2023. PMID: 36646322 Free PMC article. Clinical Trial.
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC. Lunning MA, et al. Among authors: spooner c. Am J Hematol. 2024 May;99(5):880-889. doi: 10.1002/ajh.27283. Epub 2024 Mar 19. Am J Hematol. 2024. PMID: 38504387
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang HL, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Locke FL, et al. Among authors: spooner c. Blood. 2024 Jun 27;143(26):2722-2734. doi: 10.1182/blood.2023023447. Blood. 2024. PMID: 38635762 Free PMC article.
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.
van Meerten T, Kuruvilla J, Song KW, Thieblemont C, Minnema MC, Forcade E, De Guibert S, Kersten MJ, Mutsaers PG, Wermke M, Zheng Y, Xue A, Winters JN, Nater J, Shen RR, Spooner C, Neumann F, Kim JJ, Topp MS. van Meerten T, et al. Among authors: spooner c. Am J Cancer Res. 2024 Jun 15;14(6):2905-2920. doi: 10.62347/LLXR8002. eCollection 2024. Am J Cancer Res. 2024. PMID: 39005691 Free PMC article.
Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.
Alvarado-Facundo E, Herrup R, Wang W, Colombo RE, Collins L, Ganesan A, Hrncir D, Lalani T, Markelz AE, Maves RC, McClenathan B, Mende K, Richard SA, Schmidt K, Schofield C, Seshadri S, Spooner C, Coles CL, Burgess TH, Weiss CD, Eichelberger M. Alvarado-Facundo E, et al. Among authors: spooner c. Vaccine. 2025 Jan 3;46:126669. doi: 10.1016/j.vaccine.2024.126669. Online ahead of print. Vaccine. 2025. PMID: 39754936 Free article.
Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery: The TIGHT K Randomized Clinical Trial.
O'Brien B, Campbell NG, Allen E, Jamal Z, Sturgess J, Sanders J, Opondo C, Roberts N, Aron J, Maccaroni MR, Gould R, Kirmani BH, Gibbison B, Kunst G, Zarbock A, Kleine-Brüggeney M, Stoppe C, Pearce K, Hughes M, Van Dyck L, Evans R, Montgomery HE, Elbourne D; TIGHT K investigators. O'Brien B, et al. JAMA. 2024 Sep 24;332(12):979-988. doi: 10.1001/jama.2024.17888. JAMA. 2024. PMID: 39215972 Clinical Trial.
The clinical relevance of MOG antibody testing in cerebrospinal fluid.
Reynolds M, Tan I, Nguyen K, Merheb V, Lee FXZ, Trewin BP, Lerch M, Shah S, Wolfe N, Buzzard K, Lechner-Scott J, Fabis-Pedrini M, Fok A, John N, Kneebone C, Yiannikas C, Brown DA, Kermode AG, Reddel S, Dale RC, Brilot F, Ramanathan S; Australasian MOGAD Study Group. Reynolds M, et al. Ann Clin Transl Neurol. 2024 Sep;11(9):2514-2519. doi: 10.1002/acn3.52163. Epub 2024 Jul 28. Ann Clin Transl Neurol. 2024. PMID: 39073255 Free PMC article.
210 results